Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Case series:Routine treatment+GD31, GD31: D1: 200mg QD, dissolved in 100ml of saline, intravenous drip, about 60 minutes
D2 ~ 10: 100mg QD, dissolved in 100ml of saline, intravenous drip, 30 minutes.
Sponsors
Guangzhou Eighth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1)Aged >=18 years old, gender unlimited, inpatient; (2) Novel coronavirus nucleic acid positive in pharyngeal swab specimen by real-time fluorescent RT-PCR; (3) Clinical classification is ordinary or severe patients; (4) Informed consent has been signed.
Exclusion criteria
Exclusion criteria: (1) Known or suspected to be allergic to the components of GD31; (2) Mild or critical patients in clinical classification; (3) Severe liver diseases (such as child Pugh score >=C, TBIL >=2 ULN, AST >=5 ULN), or HBsAg positive (4) Patients with severe renal insufficiency (estimated glomerular filtration rate <=30ml/min/1.73m2) or undergoing continuous renal replacement therapy, hemodialysis and peritoneal dialysis; (5) Pregnant or lactating women or women with birth plan during or within 6 months after the trial; (6) According to the judgment of the researcher, there are other situation of the patient that are not suitable for attending the trial; (7) Patients who had received chloroquine treatment within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The negative conversion rate and negative conversion time of novel coronavirus nucleic acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to Clinical recovery, TTCR;Improvement rate of lung CT;The frequency of exacerbation of respiration;Antipyretic time;Disappearance rate and disappearance time of cough;Proportion of cases from ordinary type to severe type;All-cause mortality; | — |
Countries
China
Contacts
Public ContactWeiping Cai
Guangzhou Eighth People's Hospital
Outcome results
None listed